Profile and primary treatment outcomes in membranous nephropathy

M.K. Hemanth Kumar; Jashan Sandhu; Jasvinder S. Sandhu

doi:10.15537/smj.2022.43.9.20220459

Article Figures & Data

Tables

View popup

Table 1

- Baseline charcteristics (N=122).

Clinical parameters	n (%)
Age, years (mean±SD)	43±14.6
Male	76 (62.3)
Female	46 (37.7)
Hypertension	44 (36.0)
Microscopic hematuria	16 (13.0)
Renal dysfunction	17 (14.0)
Serum creatinine, mg/dl (mean±SD)	1.04±0.58
Serum albumin, g/dl (mean±SD)	2.4±0.4
Proteinuria, g/24 hours (mean±SD)	10.5±3.1
Anti-PLA2R positive	24/37 (64.8)
Anti-PLA2R titre, RU/ml (mean±SD)	166.9±244.25

Values are presented as number and percentage (%), mean ± standard deviation (SD). PLA2R: phospholipase A2 receptor, mg/dl: milligrams per deciliter, g/dl: grams per deciliter, RU/ml: relative units per milliliter

View popup

Table 2

- Primary treatment outcomes.

Primary response	Prednisolone, cyclophosphamide (n=49)	Modified Ponticelli (n=5)	Prednisolone, tacrolimus (n=16)	Rituximab (n=50)
Males	34 (69.4)	3 (60.0)	9 (56.3)	28 (56.0)
Females	15 (30.6)	2 (40.0)	7 (43.7)	22 (44.0)
Complete remission	28 (57.0)	3 (60.0)	13 (81.0)	20 (40.0)
Partial remission	17 (34.7)	2 (40.0)	3 (19.0)	18 (36.0)
No response	4 (8.0)	0 (0.0)	0 (0.0)	12 (24.0)
Relapse	3 (6.0)	0 (0.0)	2 (13.0)	1 (2.0)